Helix Biomedix Inc. reported unaudited earnings results for the second quarter and half year ended June 30, 2012. For the quarter, the company reported total revenue of $470,522 against $693,103 a year ago. Loss from operations was $584,021 against $541,587 a year ago. Net loss and comprehensive loss was $668,299 or $0.01 per basic and diluted share against $624,875 or $0.01 per basic and diluted share a year ago. The decrease in revenue reflected declines in peptide and consumer product sales, primarily due to order and manufacturing timing, partially offset by increased license fees.

For the half year, the company reported total revenue of $1,150,944 against $1,050,731 a year ago. Loss from operations was $1,130,214 against $1,268,232 a year ago. Net loss and comprehensive loss was $1,250,137 or $0.03 per basic and diluted share against $1,334,609 or $0.03 per basic and diluted share a year ago. The decrease in net loss for the first half of 2012 compared to the same period in the prior year was primarily attributable to growth in license utilization and improved gross profit.

The company also announced the launch of its Apothederm(TM) Acne Clarifying Treatment. The new product is positioned as a four-in-one treatment that helps to reduce the appearance of blemishes and help prevent future breakouts while helping clean-up sebum and minimize pore size. The clinically tested formulation uses the company's patented SmartPeptide(TM) oligopeptide-10, based on the skin's natural defense system, in combination with salicylic acid to provide gentle, yet effective action. The product is being promoted to physicians, medical spas and select specialty retailers.